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INTRODUCTION
Various non-surgical treatments of hepatocellu-
lar carcinoma (HCC) have recently been proposed.
Such treatments include ethanol injection therapy
(PEIT), microwave coagulation therapy (PMCT),
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Abstract :
Objective :
Percutaneous treatment of hepatocellular carcinoma (HCC) located directly under the
diaphragm is problematic because ultrasonic imaging is difficult, and the lung may be in-
jured during the procedure. It has been reported that an infusion of 5% glucose solution
into the thoracic cavity enables percutaneous treatment in such cases. However, the safety
aspects of this have not been investigated. In this study, variations in heart rate and
changes in circulatory and respiratory dynamics were examined during the infusion of
artificial pleural effusion directly under the diaphragm in patients with HCC.
Method :
The subjects were 13 patients with an HCC directly under the diaphragm. About 500 ml
of a 5% glucose solution was infused into the thoracic cavity, and mean blood pressure,
heart rate, and oxygen saturation were measured. Holter electrocardiography was simul-
taneously recorded to evaluate autonomic nerve function. To analyze variations in heart
rate, the low-frequency waves (LF : 0.04-0.15 Hz), high-frequency waves (HF : 0.15-0.40 Hz,
an index of parasympathetic nerve activity), and the LF/HF ratio (index of sympathetic
nerve activity) were examined. The above parameters were measured before, during (when
infusion of the half the planned volume was complete), and after infusion were compared.
Results :
No significant changes in the mean blood pressure or heart rate were found. Oxygen satu-
ration was significantly decreased during and after the infusion. The HF value was slightly
higher after infusion and the LF value was significantly increased during infusion. The
LF/HF ratio was significantly increased during infusion, and this increase persisted
after infusion.
Conclusions :
The infusion of artificial pleural effusion had no effect on circulatory dynamics, but tran-
siently affected respiratory functions. It was also revealed that infusion stimulated the
parasympathetic nerves. J. Med. Invest. 54 : 48-53, February, 2007
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and radiofrequency ablation (RFA) (1, 2). The ap-
plication of these treatments is difficult when the
lesion cannot be imaged by ultrasonography be-
cause ultrasonic guiding is needed. The ultrasonic
imaging of lesions that are located directly under
the diaphragm is particularly difficult because the
penetration of ultrasonic waves is reduced by air
in the lung (3, 4). Moreover, the presence of the
lung in the puncture pathway increases the risk of
lung injury, making percutaneous treatment diffi-
cult in many cases (5. 6). Ohmoto and Yamakado
reported that an infusion of 300-400 ml of physi-
ological saline into the abdominal cavity of patients
with an HCC located directly under the diaphragm
separated the liver from the lung and improved
the ultrasonic imaging of the lesion (7). It has also
been reported that an infusion of a 5% glucose so-
lution into the thoracic cavity (artificial pleural ef-
fusion technique) for the same purpose increased
the efficacy and safety of the percutaneous treat-
ment of lesions located directly under the diaphragm
(8, 9). The technique was reported to be safe, but
its influence on respiratory function and circula-
tory dynamics were not investigated. Moreover,
an infusion of 400-500 ml of an artificial pleural
effusion affects respiratory function, such as de-
creasing oxygen saturation, in clinical cases, sug-
gesting that RFA after infusion may affect circula-
tory functions or the autonomic nervous system,
such as causing an increase in blood pressure due
to the severe pain involved. Studies of changes in
respiratory function, circulatory dynamics, and the
autonomic nervous system induced by the infu-
sion of artificial pleural effusion could provide im-
portant information that would permit RFA for an
HCC located directly under the diaphragm to be
performed safely. In this study, we investigated
heart beat variation and changes in circulatory and
respiratory dynamics during the infusion of an ar-
tificial pleural effusion in patients with an HCC
located directly under the diaphragm.
METHODS
Patients
The subjects were 13 patients (10 males and 3
females) with an HCC located directly under the
diaphragm. The background liver disease was HCV
in 11 patients, HBV in 1, and alcoholic liver disease
in 1, and the Child-Pugh classification was Grade A
in 11 and B in 2. All patients were diagnosed with
HCC by abdominal dynamic CT, and underwent per-
cutaneous RFA after an infusion of the artificial pleu-
ral effusion. Imformed consent to the study was ob-
tained from all patients before the start of the treat-
ment.
Artificial pleural effusion technique
A local anesthetic was administered along the
puncture pathway from the skin surface to the tho-
racic cavity, followed by the insertion of a 14-G
needle with ultrasonic guiding. 300 to 500 ml of 5%
glucose solution was then infused into the thoracic
cavity through this needle.
Measurement items
1) Holter electrocardiography
Holter electrocardiography (ECG) (SM-28 or SM-
50, Fukuda Denshi Co., Ltd., Tokyo, Japan) was re-
corded using CM5 and NASA leads. ECG changes
before and after the infusion were recorded on a com-
pact memory card (Secure Digital Memory Card).
The records were reproduced and analyzed using
an ECG analysis work station (DMW-9000H ; Fukuda
Denshi Co., Ltd., Tokyo, Japan).
2) Blood pressure
Blood pressure was measured at 3 minute inter-
vals, starting before the initiation of infusion using
an automatic hemomanometer (Olympus Co., Ltd.,
Tokyo, Japan).
3) Oxygen saturation
Oxygen saturation was continuously measured
starting before the initiation of infusion using a per-
cutaneous oxygen saturation measurement instru-
ment (Olympus Co., Ltd., Tokyo, Japan).
The above parameters were measured before,
during (when half of the planned infusion volume
was complete), and after infusion were compared.
Analysis of heart beat variation
In the analysis of heart beat variation, autonomic
nerve function was analyzed based on R-R inter-
vals on Holter ECG (10-13). The R-R interval data
were transferred to a compact memory card (Se-
cure Digital Memory Card), and subjected to Fast
Fourier Transform (FFT) using software (MenCalc/
Win GMS Co., Ltd., Tokyo, Japan) designed for
computers (Windows 2000) and the Holter ECG.
Extrasystoles were excluded from the R-R interval
data analysis so as to exclude their influence. Heart
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beat variation was analyzed in R-R intervals of 256
heart beats.
In the analysis of heart beat variation, low-
frequency waves (LF : 0.04-0.15 Hz), high-frequency
waves (HF : 0.15-0.40 Hz), and LF/HF ratios were
measured. LF components were measured to evaluate
sympathetic nerve function containing parasympa-
thetic nerve function. HF components were meas-
ured to evaluate respiration-related parasympa-
thetic nerve function (14). LF/HF was measured
to evaluate sympathetic nerve function (15). These
parameters, measured before, during (when half of
the planned volume was complete), and after infu-
sion were compared.
Statistical analysis
All measured values are presented as the means±
SD. Statistical analyses were performed using the
StatView 5.0 software program (SAS Institute Inc.,
Cary, North Carolina, USA). Between-group com-
parisons were performed using the Wilcoxon signed-
ranks test, and p<0.05 was regarded as being sig-
nificant.
RESULTS
Patients
Detailed information on the patients is shown in
Table 1. The mean infused volume of artificial pleu-
ral effusion was 415 ml (300-500 ml). No complica-
tions (hemothorax, pneumothorax, dyspnea, and
others) were caused by the artificial pleural effu-
sion technique. The infused pleural effusion disap-
peared after an average of 1.6 days following infu-
sion in the case of Child-Pugh Grade A patients,
but 3 and 4 days after infusion were required in
the 2 Child-Pugh Grade B patients.
Mean blood pressure
No significant changes were noted in mean blood
pressure before infusion (114.8±9.7mmHg), when
half of the planned volume of artificial pleural effu-
sion was complete (116.7±10.4mmHg), or after
complete infusion (117.0±9.8mmHg) (Figure 1A).
Heart rate
No significant changes were noted in heart rate
before infusion (77.5±13.3bpm), when half of the
planned volume was complete (76.8±13.9bpm), or
after complete infusion (75.4±13.3bpm) (Figure 1B).
Oxygen saturation
Oxygen saturation was significantly lower dur-
ing the period when half the planned volume was
complete than before infusion (95.4±1.9% vs. 97.0±
1.8%, P=0.02), and lower after complete infusion than
before infusion (95.4±1.8%, P=0.01) (Figure 1C). Oxy-
gen saturation was improved within 2 days after
infusion in all patients, but the time required for the
improvement was slightly longer in the case of 2
Child-Pugh Grade B patients.
Analysis of heart beat variation
No significant changes were noted in the HF value
before infusion (28.6±30.3ms2), when half of the
planned volume was complete (30.0±30.3ms2), or
after complete infusion (35.6±27.6ms2) (Figure 2A).
Table 1 Patients characteristics
age size Child-Pugh artifical pleural The time to disappearance of
case (y.o) (mm) segment sex classification effusion (ml) the artificial pleural effusion (day)
1 55 45 S3 male B 400 3
2 75 26 S8 female A 300 1
3 78 25 S8 male A 450 2
4 78 25 S7 male A 350 1
5 82 30 S8 male A 350 3
6 71 55 S4 female B 500 4
7 75 20 S4 male A 500 2
8 69 20 S7 male A 500 1
9 52 25 S8 male A 400 1
10 73 30 S7 female A 500 2
11 38 180 S7 male A 300 1
12 66 55 S2 male A 350 1
13 76 20 S7 male A 500 1
H. Fukuno, et al. Influence of an artificial pleural effusion technique５０
Figure 1 : Influence on circulatory and respiratory functions
A : No significant changes were noted in mean blood pressure between before infusion, during infusion, or after infusion.
B : No significant changes were noted in heart rate between before infusion, during infusion, or after infusion.
C : Oxygen saturation was significantly lower during infusion than before infusion and lower after infusion than before infusion.
Figure 2 : Influence on the autonomic nerve system
A : No significant changes were noted in HF between before infusion, during infusion, or after infusion.
B : The LF value was significantly higher during infusion than before infusion, while no significant change were found between
before infusion and after infusion.
C : The LF/HF ratio was significantly higher during infusion than before infusion and the increase persisted following infusion.
The Journal of Medical Investigation Vol. 54 February 2007 ５１
The LF value was significantly higher during the
period when half the planned volume was com-
plete than before infusion (48.7±44.5ms2 vs. 32.1±
31.8ms2, P=0.03), while no significant change was
found between before infusion and after complete
infusion (75.4±13.4ms2) (Figure 2B).
The LF/HF ratio was significantly higher after
half of the planned volume was infused than before
infusion (2.50±2.6ms2 vs. 1.78±13.4ms2, P=0.03) and
the increase persisted following complete infusion
(2.51±2.3ms2, P=0.25) (Figure 2C).
DISCUSSION
The infusion of an artificial pleural effusion has
recently been performed in many facilities. In ad-
dition, the advancement of non-surgical treatments
of HCC has enabled percutaneous treatment with-
out the need for laparotomy (16, 17). The efficacy
of artificial pleural effusion has been reported by
Shimada et al. and others (8).
The artificial pleural effusion technique is gen-
erally thought to have no influence on the safety
and general condition of patients (9), but these items
have not been systematically evaluated.
The infusion of artificial pleural effusion had no
effect on heart rate or blood pressure. It was ex-
pected that filling the thoracic cavity with the pleu-
ral effusion solution would compress the lung and
reduces the volume of blood trapped in the lung,
thus affecting the circulatory dynamics. However,
the possibility of such a major influence on circula-
tory dynamics may be low when the volume of pleu-
ral effusion infused is only about 500 ml.
Oxygen saturation was significantly decreased
by infusion, suggesting that filling the thoracic cav-
ity with pleural effusion causes transient atelecta-
sis and reduces oxygenation. However, non of the
patients reported any respiratory distress, and de-
creased oxygen saturation was improved by the
nasal administration of oxygen. The time required
to eliminate the pleural effusion tended to be longer
in patients with decreased liver reserve capacity,
which may have been due to a hypoalbuminemia-
induced decrease in colloidal osmotic pressure.
On comprehensive analysis of HF and LF, infu-
sion of the artificial pleural effusion had no effect
on the parasympathetic nerves with regard to an
influence on the autonomic nervous system, but the
sympathetic nerves were stimulated.
LF/HF is considered to be an index of sympa-
thetic nerve function. On comparing of LF/HF be-
tween before and after infusion, the ratio was sig-
nificantly increased, indicating that sympathetic
nerve function was enhanced. The pleural effusion
may have induced stress, and made the sympa-
thetic nerves dominant. However, the increased
LF/HF may have reflected cardiac parasympathetic
nerve activity in some patients because LF/HF is
inversely proportional to the size of the HF compo-
nent.
The HF component is generally considered to
represent parasympathetic nerve function. HF was
not affected by infusion of the artificial pleural effu-
sion. Although HF receptors (Pulmonary Strech
Receptors) are thought to be present in the tho-
racic cavity (18), stimulation by about 500 ml of pleu-
ral effusion may not have changed the HF value,
and, thus, would have a small influence on the para-
sympathetic nerves.
Regarding the analysis of heart beat variation,
the LF component is assumed to represent sympa-
thetic nerve function which contains the parasym-
pathetic nerve function. LF was significantly in-
creased during infusion, showing that infusion of
the artificial pleural effusion activated sympathetic
nerves containing parasympathetic nerves.
Overall, the infusion of artificial pleural effusion
appeared to increase the stimulation of sympa-
thetic nerves. Since paroxysmal arrhythmia may
occur under such conditions, ECG monitoring is
important during an infusion such as used herein.
In conclusion, infusion of an artificial pleural
effusion had no effect on circulatory dynamics, but
transiently affected respiratory function. Since ar-
rhythmia may occur due to the stimulation of sym-
pathetic nerves, ECG monitoring during infusion
is essential when an artificial pleural effusion is
used.
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